Cobimetinib

Contraindicated

Cobimetinib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Cobimetinib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Cobimetinib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Cobimetinib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Cobimetinib Mifepristone Korlym Increased CYP3A4 substrate with NTI exposure Details Cobimetinib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Cobimetinib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Cobimetinib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Cobimetinib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Cobimetinib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Cobimetinib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Cobimetinib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Cobimetinib Adagrasib Krazati Increased CYP3A4 substrate exposure Details Cobimetinib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Cobimetinib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Cobimetinib Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Cobimetinib Aprepitant Aponvie Increased cobimetinib plasma concentrations Details Cobimetinib Atazanavir Reyataz Increased cobimetinib plasma concentrations Details Cobimetinib Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Cobimetinib Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Cobimetinib Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Cobimetinib Boceprevir Increased cobimetinib exposure Details Cobimetinib Bosentan Decreased cobimetinib plasma concentrations Details Cobimetinib Carbamazepine Carbatrol Decreased cobimetinib plasma concentrations Details Cobimetinib Ceritinib Zykadia Increased exposure of CYP3A substrate Details Cobimetinib Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Cobimetinib Clarithromycin Biaxin Increased cobimetinib exposure Details Cobimetinib Cobicistat Tybost Increased cobimetinib exposure Details Cobimetinib Conivaptan Vaprisol Increased CYP3A substrate exposure Details Cobimetinib Crizotinib Xalkori Increased exposure of the CYP3A substrate Details Cobimetinib Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Cobimetinib Daridorexant Increased CYP3A4 substrate with NTI exposure Details Cobimetinib Diltiazem Cardizem Increased cobimetinib plasma concentrations Details Cobimetinib Dronedarone Multaq Increased cobimetinib plasma concentrations Details Cobimetinib Duvelisib Copiktra Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Cobimetinib Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Cobimetinib Efavirenz Decreased cobimetinib plasma concentrations Details Cobimetinib Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Cobimetinib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Cobimetinib Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details